查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827132

全球遗传学市场（按技术、测试类型、应用、最终用户和产品类型）预测​​ 2025-2032

Predictive Genetics Market by Technology, Test Type, Application, End User, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年预测遗传学市场将成长 58.8 亿美元，复合年增长率为 18.83%。

主要市场统计数据
基准年2024年 14.7亿美元
预计2025年 17.5亿美元
预测年份：2032年 58.8亿美元
复合年增长率（%） 18.83%

在技​​术进步、道德要求、监管限制和相关人员商业化优先事项的框架内策略性地采用预测遗传学

预测遗传学处于基因组学、临床实践和商业性创新的交叉领域。群体定序、分析流程和生物资讯学的进步，已经改变了医疗保健和生命科学领域相关人员预测疾病风险、指导治疗方法选择以及设计人群筛检方案的方式。因此，从实验室运营商到付款方再到平台提供商，相关人员必须重新调整其策略，以反映从被动诊断到预防性和预测性护理模式的加速转变。

高通量技术和模组化服务的引入降低了进入门槛，同时也提高了对分析严谨性、资料管治和临床有效性的期望。因此，决策者需要可操作的情报，以阐明技术差异化、特定应用的价值提案以及不断变化的监管和报销格局。此外，围绕知情同意、公平获取和演算法透明度的伦理考量对于公众认知和政策回应都日益重要。

本介绍总结了当前的环境，并为更深入的部分奠定了基础，这些部分分析了变革性变化、关税的影响、细分动态、区域细微差别、公司层面的策略等。透过确定关键驱动因素和限制因素，介绍列出了相关人员必须解决的策略挑战，以将预测遗传学的进步转化为永续的临床和商业性成果。

技术民主化、监管演变和综合护理模式的融合如何再形成基因预测生态系统和商业性策略

预测遗传学的格局正在被各种力量再形成，这些力量加速了临床应用，同时也使商业化变得更加复杂。技术民主化，以更廉价的定序、更复杂的检测化学和云端分析为特征，正在扩大可寻址的临床用例，同时也在分化供应商生态系统。同时，支付方和医疗系统要求提供临床效用和成本效益的有力证据，这促使供应商转向标准化、经过验证的工作流程和更强大的结果检验。

同时，法律规范也在不断发展，以应对复杂的基因组输出、演算法主导的风险评分以及跨境资料流。虽然监管的成熟提高了可预测性，但也提高了新平台和直接面向消费者产品的市场准入成本。围绕公平获取和知情同意的伦理辩论仍然至关重要，这迫使开发者和临床合作伙伴将管治通讯协定和社区参与实践制度化。

最后，市场动态青睐整合了高品质检测、解读服务和检测后咨询的整合解决方案，以实现更优质的端到端患者病人历程。仪器製造商、定序服务供应商、临床实验室和软体供应商之间的策略合作正成为扩展检验服务的主要机制。这种变革性转变凸显了灵活应变的经营模式、有针对性的临床证据产生以及积极主动的监管和支付方参与的必要性，以实现预测遗传学的前景。

了解 2025 年美国关税调整对遗传学预测供应链和定价动态的营运、采购和竞争影响

美国2025年关税变化将为整个基因预测价值链的营运和采购决策带来新的变数。某些试剂和设备组件的进口关税上调可能会影响实验室和定序中心的成本结构，促使其重新评估筹资策略和库存管理。为此，许多机构正在评估近岸外包机会、替代供应商和长期合同，以降低贸易主导的价格波动所带来的风险。

进口限制也影响了竞争格局，有利于拥有国内製造能力的垂直整合供应商，同时挤压依赖进口耗材和专用设备的小型服务实验室。因此，供应商可能会优先投资于供应链弹性，例如认证多家供应商、增加安全库存以及投资于能够相容于更多试剂的模组化平台。

除了对采购的直接影响外，关税主导的成本压力还可能改变与付款人和客户的价格谈判，增强对营运效率的关注，并加速中小企业的整合。因此，相关人员应密切关注关税政策的发展，量化产品和服务线的风险敞口，并主动与供应商和客户沟通，沟通潜在影响和缓解措施。

全面的细分洞察，揭示技术、测试类型、应用程式、最终用户和产品类型如何交叉以定义商业机会和策略重点

细緻的细分视角可以明确价值创造的领域以及哪些途径需要差异化策略。从技术角度来看，微阵列平台仍然适用于群体层级的检测，并细分为比较基因组杂合反应和表达微阵列方案，而次世代定序包括标靶定序、全外EXOME定序和全基因组定序，以适应不同深度和广度的研究。考虑到测试类型，癌症筛检为 BRCA 检测、大肠直肠癌筛检和肺癌筛检提供了不同的临床和商业性轨迹；携带者筛检范围从扩展面板到单基因携带者检测；药物基因组学包括与处方工作流程紧密结合的 CYP 和药物代谢测试；产前检测区分侵入性和非侵入神经退化风险整合

基于应用的细分显示，预测遗传学在心血管疾病（如心臟病和中风）、感染疾病监测和疫情应对、神经系统疾病、肿瘤学（包括乳癌、结直肠癌和肺癌等子领域）以及诊断产量至关重要的罕见疾病中发挥着重要作用。最终用户包括学术研究机构、诊断实验室、直接面向消费者的管道和医院，每个用户都有不同的购买週期、检验要求和上市时间预期。产品类型包括消耗品、仪器、服务和软体。服务包括遗传咨询、定序服务和检测服务，其中定序服务值得特别关注，因为它们细分为 NGS 和 PCR 服务。总之，这些细分层告知应优先考虑证据产生、产品开发和商业投资，以使技术能力与临床工作流程和付款人期望保持一致。

亚太地区、欧洲、中东和非洲的区域动态和监管细微差别决定了招募途径、报销和营运重点

区域动态在塑造预测遗传学领域的需求、报销途径和监管预期方面发挥着至关重要的作用。在美洲，强劲的私人支付市场和活跃的直接面向消费者的管道正在支持临床导向检测的快速普及，但报销政策的差异性使得在关键治疗领域开展有针对性的证据开发成为必要。同时，欧洲、中东和非洲的国家管理体制和公共卫生优先事项各不相同。在某些地区，集中监管协调与国家报销差异并存，使得区域卫生经济模式和相关人员的参与对于市场进入和扩张至关重要。

亚太地区多元化的医疗保健架构和对基因组研究的强劲公共投资，既带来了市场进入机会，也带来了营运复杂性。有些市场优先考虑全民筛检和国家基因组策略，而有些市场则是新兴市场，有报销限制。跨地区比较分析显示，监管时间表、数据在地化要求和采购惯例存在显着差异，这迫使企业在不同地区调整其定价、证据和伙伴关係方式。最后，区域人才库、实验室认证标准和供应链布局会影响製造、服务中心和研究合作的选址，这进一步凸显了区域特定策略规划的重要性。

竞争动态和公司层面的策略结合技术差异化、服务整合、伙伴关係和证据产生来获得预测遗传学的价值

基因预测领域的竞争优势取决于技术领先地位、服务整合以及透过检验证据证明临床价值的能力。主要企业正在采取不同的方法：一些公司专注于仪器创新和专有化学技术，以确保耗材收益来源；另一些公司专注于软体和解读平台，以获取下游利润并实现多组体学整合；实验室网路和定序服务供应商透过标准化工作流程和扩大地理覆盖范围来实现规模化。连接仪器製造商和临床实验室、软体供应商和生物製药公司、咨询服务机构和付款人的策略伙伴关係关係和跨部门联盟，正成为提供端到端解决方案日益重要的机制。

智慧财产权和监管核准仍然是差异化因素，尤其对于伴随诊断和与报销驱动适应症相关的检测。投资于以患者为中心的服务（例如综合遗传咨询和长期结果追踪）的公司更有能力满足付款人对已证实效用的期望。随着大型公司收购利基技术、解读能力或区域侦测能力以加速市场进入，併购正在持续重塑市场格局。总体而言，竞争成功将取决于能否将技术差异化与检验的临床路径、可扩展的营运以及完善的资料管治框架相结合。

为行业领导者提供可操作且实用的建议，以协调伙伴关係、证据策略、供应链弹性和数据管治与可扩展的商业化计划

行业领导者应采取多管齐下的务实方法，在管理风险的同时实现成长。首先，优先发展将检测与解读和咨询服务相结合的策略合作伙伴关係，从而创造符合临床工作流程、价值更高、黏性更强的产品。其次，投资符合付款人要求和区域医疗技术援助框架的有针对性的临床证据项目。在优先适应症中展示疗效改善和成本抵消，以降低进入门槛并支持报销谈判。第三，透过供应商多元化、可行的试剂替代品以及选择性近岸外包来增强供应链的韧性，以缓解关税和物流中断的影响。

此外，建立严格的资料管治和隐私实践对于维护信任和满足不断变化的监管期望至关重要。这包括透明的知情同意流程、安全的分析环境以及公平的存取机制。公司还应评估将直接面向消费者和临床医生中介管道相结合的混合商业模式，以在保持临床监管的同时扩大覆盖范围。最后，领导者必须致力于员工发展和临床教育计划，以提高临床医生和付款人的基因素养，促进适当的检测利用，并减少实施过程中的摩擦。

一种透明的混合调查方法，结合专家访谈、二次证据综合、分割映射和强大的检验通讯协定

本研究采用混合调查方法，整合了主要研究和次要研究。主要输入包括与临床负责人、实验室主任、付款人和技术供应商的结构化访谈，并辅以检验访谈以检验新出现的假设。次要分析涵盖同行评审文献、监管指南、临床实践指南和行业技术简报，以确认概念与现行标准一致。资料三角测量技术可协调不同的观点，并检验不同资讯来源的主题结论。

分析方法包括细分图谱、技术就绪评估、监管路径分析和基于情境的敏感度评估。品管包括资讯来源三角测量、受访者检验和内部同行评审，以确保稳健性并减少偏差。我们承认调查方法有局限性，例如各国报销实践的差异和快速发展的法规环境。在适用的情况下，我们会将研究结果具体化，而不是将其视为通用处方笺。最后，建议基于可重复的分析步骤，使相关人员能够根据其特定的地理、治疗领域或商业性环境调整此框架。

关于综合解决方案、本地化策略、供应链弹性和基于证据的参与如何决定遗传学预测成功的总结

基因预测正从愿景转化为行动，但要充分发挥其潜力，需要在技术、证据生成和相关人员参与方面进行有针对性的协调。本报告始终贯穿着一个主题：结合高品质检测、严谨解读和以患者为中心的服务的整合解决方案，在临床应用和付款人接受度方面将优于单点解决方案。此外，地理和监管的细微差别要求我们采取量身定制的方法，而非一刀切的部署方式，而诸如关税变化等供应链动态可能会对营运可行性产生重大影响。

展望未来，那些能够展现临床和经济价值、保持灵活且富有弹性的筹资策略并投资于透明管治以维护信任的组织将会取得成功。策略伙伴关係和有针对性的证据项目将加速其应用，而员工培训和临床医生的参与将减少应用过程中的摩擦。总而言之，预测遗传学的扩展之路将取决于将技术创新与现实世界的临床工作流程、报销现实和负责任的资料管理相结合。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 将多基因风险评分整合到常规临床决策支援工作流程中以预防慢性疾病
  • 扩展直接面向消费者的基因检测平台，透过人工智慧解读提供血统和健康风险洞察
  • 利用药物基因组学分析个人化肿瘤治疗方法并减少癌症治疗的药物不良反应
  • 奈米孔定序的进步使得公共卫生环境中的即时病原体监测和疫情预测成为可能
  • 基因组学Start-Ups与远端医疗提供者建立策略合作伙伴关係，提供 DNA检测套组和居家咨询
  • 实施符合 GDPR 的基因组资料共用框架，促进跨国研究合作
  • 采用区块链技术提高基因数据管理和患者同意的安全性和透明度

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 预测遗传学市场（按技术）

  • 微阵列
    • 比较基因组杂合反应
    • 表达微阵列
  • 次世代定序
    • 标靶定序
    • 全EXOME定序
    • 全基因测序
  • 聚合酵素链锁反应
    • 数位PCR
    • 即时PCR
  • 桑格定序

9. 预测遗传学市场（按测试类型）

  • 癌症筛检
    • BRCA检测
    • 大肠癌筛检
    • 肺癌筛检
  • 携带者筛检
    • 延长航母
    • 单基因携带者
  • 药物基因组学
    • CYP检测
    • 药物代谢检测
  • 产前检查
    • 侵入性产前检测
    • 非侵入性产前检测
  • 风险评估
    • 心血管风险
    • 神经退化风险

第 10 章预测遗传学市场（按应用）

  • 心血管系统
    • 心臟病
    • 中风
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学
    • 乳癌
    • 大肠直肠癌
    • 肺癌
  • 罕见疾病

第 11 章预测遗传学市场（按最终用户）

  • 学术研究机构
  • 诊断实验室
  • 消费者
  • 医院

第 12 章预测遗传学市场（依产品类型）

  • 耗材
  • 装置
  • 服务
    • 遗传咨询
    • 定序服务
      • NGS服务
      • PCR服务
    • 测试服务
  • 软体

第十三章预测遗传学市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章预测遗传学市场（按群体）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按国家/地区分類的预测遗传学市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Myriad Genetics, Inc.
    • Invitae Corporation
    • Natera, Inc.
    • 23andMe Holding Co.
    • Fulgent Genetics, Inc.
    • Guardant Health, Inc.
    • Color Health, Inc.
    • Helix OpCo, Inc.
    • Gene by Gene, Ltd.
    • Genomic Prediction, Inc.
Product Code: MRR-8903005C49A9

The Predictive Genetics Market is projected to grow by USD 5.88 billion at a CAGR of 18.83% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.47 billion
Estimated Year [2025] USD 1.75 billion
Forecast Year [2032] USD 5.88 billion
CAGR (%) 18.83%

A strategic introduction to predictive genetics that frames technological advances, ethical imperatives, regulatory constraints, and commercialization priorities for stakeholders

Predictive genetics stands at the intersection of genomic science, clinical practice, and commercial innovation. Advances in sequencing, analytical pipelines, and bioinformatics have transformed how actors across healthcare and life sciences anticipate disease risk, guide therapeutic choices, and design population-level screening programs. As a result, stakeholders from laboratory operators to payers and platform providers must recalibrate strategy to reflect an accelerating shift from reactive diagnosis to preventive and predictive care models.

The introduction of high-throughput technologies and modular service offerings has lowered barriers to entry while raising expectations for analytical rigor, data governance, and clinical validity. Consequently, decision-makers need actionable intelligence that clarifies technology differentiation, application-specific value propositions, and the evolving regulatory and reimbursement landscape. Moreover, ethical considerations around consent, equity of access, and algorithmic transparency are increasingly central to both public perception and policy responses.

This introduction synthesizes the current environment and sets the stage for deeper sections that analyze transformative shifts, tariff impacts, segmentation dynamics, regional nuances, and company-level strategies. By framing key drivers and constraints, this opening establishes the strategic questions stakeholders must address to translate predictive genetics advances into sustainable clinical and commercial outcomes.

How converging technological democratization, regulatory evolution, and integrated care models are reshaping the predictive genetics ecosystem and commercial playbooks

The landscape of predictive genetics is being reshaped by converging forces that accelerate clinical translation even as they complicate commercialization. Technological democratization-characterized by more affordable sequencing, refined assay chemistries, and cloud-enabled analytics-has expanded the addressable clinical use cases while fragmenting the supplier ecosystem. At the same time, payers and health systems are demanding robust evidence of clinical utility and cost-effectiveness, which is driving providers toward standardized validated workflows and stronger outcome data.

Concurrently, regulatory frameworks are evolving to account for complex genomic outputs, algorithm-driven risk scores, and cross-border data flows. This regulatory maturation increases predictability but also raises the cost of market entry for novel platforms and direct-to-consumer offerings. Ethical debates around equitable access and informed consent remain salient, prompting developers and clinical partners to institutionalize governance protocols and community engagement practices.

Finally, market dynamics are favoring integrated solutions that bundle high-quality assays, interpretation services, and post-test counseling, enabling better end-to-end patient journeys. Strategic collaborations between instrument manufacturers, sequencing service providers, clinical laboratories, and software vendors are becoming a primary mechanism to scale validated services. These transformative shifts underscore the need for adaptive business models, targeted clinical evidence generation, and proactive regulatory and payer engagement to realize the promise of predictive genetics.

Understanding the operational, sourcing, and competitive consequences of United States tariff adjustments in 2025 that influence predictive genetics supply chains and pricing dynamics

Tariff changes in the United States during 2025 have introduced a new variable into operational and procurement decisions across the predictive genetics value chain. Increased import duties on certain reagents and instrumentation components can affect cost structures for laboratories and sequencing centers, prompting a reassessment of sourcing strategies and inventory management. In response, many organizations are evaluating nearshoring opportunities, alternative suppliers, and longer-term contracts to mitigate exposure to trade-driven price volatility.

Import constraints also influence the competitive landscape by advantaging vertically integrated suppliers with domestic manufacturing capabilities while pressuring smaller service labs that rely on imported consumables and specialized instruments. Consequently, providers may prioritize investments in supply chain resilience, such as qualifying multiple vendors, increasing safety stock, or investing in modular platforms that accept a broader range of reagents.

Beyond immediate procurement impacts, tariff-driven cost pressures can alter pricing negotiations with payers and clients, intensify the focus on operational efficiency, and accelerate consolidation among smaller players. Therefore, stakeholders should monitor tariff policy developments closely, quantify exposure across product and service lines, and proactively engage suppliers and customers to communicate potential impacts and mitigation strategies.

Comprehensive segmentation insights that reveal how technology, test type, application, end user, and product type intersect to define opportunity and strategic prioritization

A nuanced segmentation lens clarifies where value is created and which pathways demand differentiated strategies. From a technology perspective, microarray platforms remain relevant for population-level assays and are subdivided into comparative genomic hybridization and expression microarray protocols, while next generation sequencing encompasses targeted sequencing, whole exome sequencing, and whole genome sequencing tailored to varying depth and breadth of inquiry; polymerase chain reaction technologies split into digital PCR and real time PCR for high-sensitivity, rapid assays, and legacy Sanger sequencing persists for confirmatory workflows. When considering test type, cancer screening occupies substantial focus with BRCA testing, colorectal cancer screening, and lung cancer screening representing distinct clinical and commercial trajectories; carrier screening ranges from expanded panels to single gene carrier tests, pharmacogenomics includes CYP testing and drug metabolism testing that align tightly with prescribing workflows, prenatal testing differentiates invasive prenatal testing from non invasive prenatal testing, and risk assessment spans cardiovascular risk and neurodegenerative risk applications that require longitudinal data integration.

Application-based segmentation reveals that predictive genetics serves cardiovascular indications such as heart disease and stroke, infectious disease surveillance and outbreak response, neurological disorders, oncology with subdomains like breast cancer, colorectal cancer, and lung cancer, and rare diseases where diagnostic yield is critical. End users include academic research institutes, diagnostic laboratories, direct-to-consumer channels, and hospitals, each with distinct purchasing cycles, validation requirements, and go-to-market expectations. Product types range across consumables, instruments, services, and software; services warrant special attention as they include genetic counseling, sequencing services and testing services, with sequencing service subdivided into NGS service and PCR service. Taken together, these segmentation layers inform where to prioritize evidence generation, product development, and commercial investment to align technical capabilities with clinical workflows and payer expectations.

Regional dynamics and regulatory nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine adoption pathways, reimbursement, and operational priorities

Regional dynamics play a decisive role in shaping demand, reimbursement pathways, and regulatory expectations across the predictive genetics domain. In the Americas, robust private payer markets and active direct-to-consumer channels drive rapid adoption of clinically oriented assays, yet heterogeneity in coverage policies necessitates targeted evidence generation for key therapeutic areas. Meanwhile, Europe, Middle East & Africa presents a patchwork of national regulatory regimes and public health priorities; centralized regulatory harmonization in some jurisdictions coexists with country-level reimbursement variability, making localized health economic models and stakeholder engagement essential for market entry and scale.

In the Asia-Pacific region, diverse healthcare architectures and substantial public investment in genomic initiatives create both opportunities and operational complexity. Some markets emphasize population-scale screening and national genomics strategies, while others remain nascent with constrained reimbursement. Cross-region comparative analyses highlight that regulatory timelines, data localization requirements, and procurement practices differ materially, so companies must adapt pricing, evidence, and partnership approaches by geography. Finally, regional talent pools, laboratory accreditation standards, and supply chain footprints influence where to site manufacturing, service centers, and research collaborations, reinforcing the importance of geography-specific strategic planning.

Competitive dynamics and company-level strategies that combine technology differentiation, service integration, partnerships, and evidence generation to capture value in predictive genetics

Competitive positioning in predictive genetics is defined by technology leadership, service integration, and the ability to demonstrate clinical value through validated evidence. Key companies are adopting distinct approaches: some focus on instrument innovation and proprietary chemistries to lock in consumable revenue streams, others emphasize software and interpretation platforms to capture downstream margin and enable multi-omic integration, while laboratory networks and sequencing service providers scale by standardizing workflows and expanding geographic reach. Strategic partnerships and cross-sector alliances-linking instrument makers with clinical laboratories, software vendors with biopharma, and counseling services with payers-are increasingly prominent as mechanisms to deliver end-to-end solutions.

Intellectual property and regulatory approvals remain differentiators, particularly for assays tied to companion diagnostics or reimbursement-sensitive indications. Companies investing in patient-centric services, such as integrated genetic counseling and longitudinal outcome tracking, are positioned to meet payer expectations for demonstrated utility. Mergers and acquisitions continue to reconfigure the landscape as larger players acquire niche technologies, interpretation capabilities, or regional laboratory capacity to accelerate market access. Overall, competitive success will hinge on the ability to combine technological differentiation with validated clinical pathways, scalable operations, and robust data governance frameworks.

Actionable and pragmatic recommendations for industry leaders to align partnerships, evidence strategy, supply chain resilience, and data governance with scalable commercialization plans

Industry leaders should adopt a multi-pronged, pragmatic approach to capture growth while managing risk. First, prioritize strategic alliances that integrate assays with interpretation and counseling services, thereby creating higher-value, stickier offerings that align with clinical workflows. Second, invest in targeted clinical evidence programs aligned with payer requirements and local HTA frameworks; demonstrating improved outcomes or cost offsets in priority indications will reduce access barriers and support reimbursement negotiations. Third, reinforce supply chain resilience through supplier diversification, validated alternative reagents, and selective nearshoring to mitigate tariff and logistics disruptions.

Additionally, establishing rigorous data governance and privacy practices will be critical to maintaining trust and meeting evolving regulatory expectations; this includes transparent consent processes, secure analytics environments, and mechanisms for equitable access. Firms should also evaluate hybrid business models that combine direct-to-consumer channels with clinician-mediated pathways to expand reach while maintaining clinical oversight. Lastly, leaders must commit to workforce development and clinical education initiatives to broaden genetics literacy among clinicians and payers, thereby accelerating appropriate test utilization and reducing implementation friction.

Transparent mixed-methods research methodology combining expert interviews, secondary evidence synthesis, segmentation mapping, and robust validation protocols

This research employs a mixed-methods approach that integrates primary qualitative insights with secondary evidence synthesis and methodological triangulation. Primary inputs include structured interviews with clinical leaders, laboratory directors, payers, and technology vendors, supplemented by validation interviews that test emerging hypotheses. Secondary analysis encompasses peer-reviewed literature, regulatory guidance, clinical practice guidelines, and industry technical briefs to ensure conceptual alignment with current standards. Data triangulation methods reconcile divergent viewpoints and validate thematic conclusions across sources.

Analytical techniques include segmentation mapping, technology readiness assessment, regulatory pathway analysis, and scenario-based sensitivity reviews. Quality controls involve source triangulation, respondent validation, and internal peer review to ensure robustness and reduce bias. Limitations of the methodology are acknowledged, including variability in national reimbursement practices and the rapidly evolving regulatory environment; where applicable, findings are contextualized rather than presented as universal prescriptions. Finally, recommendations are grounded in repeatable analytical steps to enable stakeholders to adapt the framework to specific geographies, therapeutic areas, or commercial contexts.

Concluding synthesis of how integrated solutions, tailored regional strategies, supply chain resilience, and evidence-based engagement will determine success in predictive genetics

Predictive genetics is transitioning from promise to practiced utility, but realizing its full potential requires deliberate orchestration across technology, evidence generation, and stakeholder engagement. Throughout this report, a consistent theme emerges: integrated solutions that combine high-quality assays, rigorous interpretation, and patient-centered services outperform point solutions in clinical adoption and payer acceptance. Moreover, geographic and regulatory nuances demand tailored approaches rather than one-size-fits-all rollouts, and supply chain dynamics such as tariff changes can materially affect operational viability.

Looking ahead, success will favor organizations that can demonstrate clinical and economic value, maintain flexible and resilient sourcing strategies, and invest in transparent governance to preserve trust. Strategic partnerships and targeted evidence programs will accelerate uptake, while workforce education and clinician engagement will reduce implementation friction. In sum, the pathway to scaling predictive genetics hinges on aligning technological innovation with real-world clinical workflows, reimbursement realities, and responsible data stewardship.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of polygenic risk scoring in routine clinical decision support workflows for chronic disease prevention
  • 5.2. Expansion of direct-to-consumer genetic testing platforms offering ancestry and health risk insights through AI-driven interpretation
  • 5.3. Use of pharmacogenomic profiling to personalize oncology treatment regimens and reduce adverse drug reactions in cancer care
  • 5.4. Advancements in nanopore sequencing enabling real-time pathogen surveillance and outbreak prediction in public health settings
  • 5.5. Strategic partnerships between genomic startups and telemedicine providers to deliver at-home DNA test kits and consultations
  • 5.6. Implementation of GDPR-compliant genomic data sharing frameworks for cross-border research collaborations
  • 5.7. Adoption of blockchain technology to enhance security and transparency in genetic data management and patient consents

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Predictive Genetics Market, by Technology

  • 8.1. Microarray
    • 8.1.1. Comparative Genomic Hybridization
    • 8.1.2. Expression Microarray
  • 8.2. Next Generation Sequencing
    • 8.2.1. Targeted Sequencing
    • 8.2.2. Whole Exome Sequencing
    • 8.2.3. Whole Genome Sequencing
  • 8.3. Polymerase Chain Reaction
    • 8.3.1. Digital PCR
    • 8.3.2. Real Time PCR
  • 8.4. Sanger Sequencing

9. Predictive Genetics Market, by Test Type

  • 9.1. Cancer Screening
    • 9.1.1. BRCA Testing
    • 9.1.2. Colorectal Cancer Screening
    • 9.1.3. Lung Cancer Screening
  • 9.2. Carrier Screening
    • 9.2.1. Expanded Carrier
    • 9.2.2. Single Gene Carrier
  • 9.3. Pharmacogenomics
    • 9.3.1. CYP Testing
    • 9.3.2. Drug Metabolism Testing
  • 9.4. Prenatal Testing
    • 9.4.1. Invasive Prenatal Testing
    • 9.4.2. Non Invasive Prenatal Testing
  • 9.5. Risk Assessment
    • 9.5.1. Cardiovascular Risk
    • 9.5.2. Neurodegenerative Risk

10. Predictive Genetics Market, by Application

  • 10.1. Cardiovascular
    • 10.1.1. Heart Disease
    • 10.1.2. Stroke
  • 10.2. Infectious Diseases
  • 10.3. Neurological Disorders
  • 10.4. Oncology
    • 10.4.1. Breast Cancer
    • 10.4.2. Colorectal Cancer
    • 10.4.3. Lung Cancer
  • 10.5. Rare Diseases

11. Predictive Genetics Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Direct To Consumer
  • 11.4. Hospitals

12. Predictive Genetics Market, by Product Type

  • 12.1. Consumables
  • 12.2. Instruments
  • 12.3. Services
    • 12.3.1. Genetic Counseling
    • 12.3.2. Sequencing Service
      • 12.3.2.1. NGS Service
      • 12.3.2.2. PCR Service
    • 12.3.3. Testing Service
  • 12.4. Software

13. Predictive Genetics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Predictive Genetics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Predictive Genetics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Myriad Genetics, Inc.
    • 16.3.2. Invitae Corporation
    • 16.3.3. Natera, Inc.
    • 16.3.4. 23andMe Holding Co.
    • 16.3.5. Fulgent Genetics, Inc.
    • 16.3.6. Guardant Health, Inc.
    • 16.3.7. Color Health, Inc.
    • 16.3.8. Helix OpCo, Inc.
    • 16.3.9. Gene by Gene, Ltd.
    • 16.3.10. Genomic Prediction, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PREDICTIVE GENETICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PREDICTIVE GENETICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PREDICTIVE GENETICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310.